Cadre Holdings: Saving Lives and Unlocking Value: Initiating at Overweight with YE27 PT of $40

Research evidence excerpt

Cadre Holdings: Saving Lives and Unlocking Value: Initiating at Overweight with YE27 PT of $40

Tomohiko Sano AC North America Equity Research

(1-212) 622-1099 27 July 2026 J P M O R G A N

tomohiko.sano@jpmorgan.com

Risks to Rating and Price Target

Tied to Government Funding: Cadre’s revenues are partially dependent on U.S.

federal, state, and international government budgets, and reductions or shifts in public

safety or defense spending for its products could materially impact sales and

profitability.

Raw Material Inflation & Fixed Cost Contracts: Raw material inputs include

SpectraShield, Kevlar, Dyneema, and Twaron, among others, and any input cost

increases could drive headwinds, particularly in the company's direct government

contracts, which are largely fixed price.

M&A Integration: Failure to successfully integrate recent acquisitions (incl. Alpha

Safety, Zircaloy, TYR Tactical, etc.) could result in operational inefficiencies, missed

synergies, or margin contraction.

Increasing Leverage & Volatile FCF: With M&A serving as a key pillar of Cadre's

growth profile since its IPO, overpaying for an acquisition, overleveraging the balance

sheet, or acquiring a business with a materially lower FCF profile could pressure the

company's ability to delever and sustain cash generation.

Competitive Pressure: Cadre faces competition from both large multinationals and

specialized local players in its markets, and failure to maintain product innovation or

pricing power could erode market share or compress margins.

Nuclear Policy Risks: The recent executive order suspending the plutonium

downblending program introduces risks of additional government funding shifts or

changes in capital allocation, which could materially impact Cadre’s nuclear safety end

market.